DEVA Holding Çerkezköy II manufacturing sites located at the 110 km distance to Istanbul, founded on an area of 67,551 m2 in Çerkezköy Organized Industrial Zone, with closed sites of 18,742 m2, comprise of state-of-the-art manufacturing buildings where solid oncology, sterile liquid oncology, animal health products and APIs are manufactured.

Solid Oncology Manufacturing Unit

Products in tablet and capsule form are manufactured in the solid oncology manufacturing unit. In 2017, Tamoxifen 10 and 20 mg launched for the Turkish market as well as Temozolomide capsule US product launched for the US market were realized in 6 different forms, i.e. 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg.

Sterile Liquid Oncology Manufacturing Unit

Products in sterile liquid and sterile lyophilized powder forms are manufactured in Sterile Liquid Oncology Manufacturing Unit.

The manufacturing quantity of the unit of 616,326 units in 2016 was 569,855 units in 2017.

Sterile Animal Health Products Manufacturing Unit

Products in sterile suspension and intramammary pomade form are manufactured in Sterile Animal Health Products Manufacturing Unit.
The manufacturing quantity of the unit, which was 233,795 units in 2016 was 177,380 units in 2017.

API Manufacturing Units

The sites have four separate designated API manufacturing units: Non-betalactam API, Betalactam Non-sterile API, Betalactam Sterile API, and Oncolytic API.

The API manufacturing quantity, which was 14,257 kg in 2016, was 5,977 in 2017. Manufacturing operations are in accordance with customer requests. Twenty different API products can be manufactured in non-betalactam, betalactam and oncology fields.

From the 5,977 kg product, 814 kg Non-Betalactam products, 4,835 kg Betalactam products and 328 kg Oncology products were manufactured.

Validation manufacturing for the new products, 2-methyl-2-phenoxy-propionate sodium, Ricobendazole HCl in the Non-betalactam unit and Lenalidomide and Pomalidomide in the oncolytic units were performed in 2017.

In API manufacturing, the toxic gases arising from reaction are neutralized before being released to the atmosphere to minimize the environmental effects resulting from manufacturing activities.

The API manufacturing units successfully passed 3 different European customers’ inspections in 2017.

The capacity utilization rate of Çerkezköy Main and API Manufacturing sites is 74%.